Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3377-3387

  Li, Na ^a   Luo, Heng Cong ^a   Yang, Chuan ^a   Deng, Jun Jie ^a   Ren, Meng ^a   Xie, Xiao Ying ^a   Lin, Diao Zhu ^a   Yan, Li ^a   Zhang, Li Ming ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Diabetic foot ulceration; Gene carrier; Matrix metalloproteinase 9; Small interfering RNAs

Indexed keywords

BETA CYCLODEXTRIN; GELATINASE B; POLYAMIDOAMINE; POLYMER; SMALL INTERFERING RNA; STREPTOZOCIN; BETA CYCLODEXTRIN DERIVATIVE; CATION; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; COMPLEX FORMATION; COMPOSITE MATERIAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE LOCATION; GENETIC TRANSFECTION; MM9 GENE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYMERIZATION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; QUANTITATIVE STUDY; RAT; RAT MODEL; REAL TIME POLYMERASE CHAIN REACTION; RNA GENE; SKIN FIBROBLAST; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WOUND CLOSURE; WOUND HEALING; ANIMAL; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROBLAST; GENE EXPRESSION; GENETICS; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; BETA-CYCLODEXTRINS; CATIONS; CELL LINE; CELL SURVIVAL; DIABETES MELLITUS, EXPERIMENTAL; FIBROBLASTS; GENE EXPRESSION; MATRIX METALLOPROTEINASE 9; NANOPARTICLES; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; TRANSFECTION; WOUND HEALING;

EID: 84904444093     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S66368     Document Type: Article

References (33)

1. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005; 366(9498): 1719-1724.
2. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H. Expression of matrix-metalloproteinases and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia. 2002; 45(7): 1011-1016.
3. Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care. 2005; 28(2): 461-471.
4. Wysocki AB, Staiano-Coico L, Grinneill F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol. 1993; 101(1): 64-68.
5. Ambrosch A, Halevy D, Fwity B, Brin T, Lobmann R. Effect of daptomycin on local interleukin-6, matrix metalloproteinase-9, and metallopeptidase inhibitor 1 in patients with MRSA-infected diabetic foot. Int J Low Extrem Wounds. 2013; 12(2): 100-105.
6. Dinh T, Tecilazich F, Kafanas A, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012; 61(11): 2937-2947.
7. Yang C, Zhu P, Yan L, Chen L, Meng R, Lao G. Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats. J Am Podiatr Med Assoc. 2009; 99(6): 489-496.
8. Liu Y, Min D, Bolton T, et al. Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers. Diabetes Care. 2009; 32(1): 117-119.
9. Reiss MJ, Han YP, Garcia E, Goldberg M, Yu H, Garner WL. Matrix metalloproteinase-9 delays wound healing in a murine wound model. Surgery. 2010; 147(2): 295-302.
10. Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Kelman Cohen I. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Repair Regen. 1997; 5(1): 23-32.
11. Trengove NJ, Stacey MC, MacAuley S, et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 1999; 7(6): 442-452.
12. Lauer G, Sollberg S, Cole M, et al. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J Invest Dermatol. 2000; 115(1): 12-18.
13. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391(6669): 806-811.
14. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science. 2001; 293(5532): 1146-1150.
15. Hannon GJ. RNA interference. Nature. 2002; 418(6894): 244-251.
16. Sharp PA. RNAi and double-strand RNA. Genes Dev. 1999; 13(2): 139-141.
17. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836): 494-498.
18. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001; 409(6818): 363-366.
19. Fuchs U, Damm-Welk C, Borkhardt A. Silencing of disease-related genes by small interfering RNAs. Curr Mol Med. 2004; 4(5): 507-17.
20. Cheng JC, Moore TB, Sakamoto KM. RNA interference and human disease. Mol Genet Metab. 2003; 80(1-2): 121-8.
21. Joo MK, Yhee JY, Kim SH, Kim K. The potential and advances in RNAi therapy: Chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers. J Control Release. 2014.
22. Mao CQ, Du JZ, Sun TM, et al. A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy. Biomaterials. 2011; 32(11): 3124-3133.
23. Hallaj-Nezhadi S, Lotfipour F, Dass CR. Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy. Pharmazie. 2010; 65(12): 855-859.
24. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12(4): 492-503.
25. Georgiou TK, Vamvakaki M, Patrickios CS, Yamasaki EN, Phylactou LA. Nanoscopic cationic methacrylate star homopolymers: synthesis by group transfer polymerization, characterization and evaluation as transfection reagents. Biomacromolecules. 2004; 5: 2221-2229.
26. Cryan SA, Holohan A, Donohue R, Darcy R, O'Driscoll CM. Cell transfection with polycationic cyclodextrin vectors. Eur J Pharm Sci. 2004; 21: 625-633.
27. Xu FJ, Zhang ZX, Ping Y, Li J, Kang ET, Neoh KG. Star-shaped cationic polymers by atom transfer radical polymerization from beta-cyclodextrin cores for nonviral gene delivery. Biomacromolecules. 2009; 10: 285-293.
28. Srinivasachari S, Fichter KM, Reineke TM. Polycationic beta-cyclodextrin "click clusters": monodisperse and versatile scaffolds for nucleic acid delivery. J Am Chem Soc. 2008; 130: 4618-4627.
29. Deng J, Li N, Mai KJ, Yang C, Yan L, Zhang LM. Star-shaped polymers consisting of a b-cyclodextrin core and poly(amidoamine) dendron arms: binding and release studies with methotrexate and siRNA. J Mater Chem. 2011; 21: 5273-5281.
30. Ma K, Hu MX, Qi Y, et al. PAMAM-triamcinolone acetonide conjugate as a nucleus-targeting gene carrier for enhanced transfer activity. Biomaterials. 2009; 30: 6109-6118.
31. Patil ML, Zhang M, Betigeri S, Taratula O, He H, Minko T. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. Bioconjug Chem. 2008; 19(7): 1396-1403.
32. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003; 24(7): 1121-1131.
33. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998; 98(5): 2045-2076.